Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz

angelp/iStock via Getty Images Axsome Therapeutics ( NASDAQ: AXSM ) has reached an agreement with Sandoz ( OTCQX:SDZNY ) to dismiss the patent litigation related to Axsome’s product Sunosi (solriamfetol), it said on Wednesday. The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by Sandoz of an Abbreviated New Drug Application to the U.S.

Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. Sandoz ( OTCQX:SDZNY ) withdrew its ANDA for a generic equivalent of Sunosi, and, as a result, the litigation has been dismissed without prejudice. Source: Press Release More on Axsome Therapeutics, Sandoz Group AG, etc.

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade) BofA upgrades Axsome to buy, cites upcoming Auvelity data Axsome Therapeutics GAAP EPS of -$1.67 misses by $0.34, revenue of $87.

2M beats by $0.27M.